Hepatoprotective and anti‐fibrotic functions of interleukin‐22: Therapeutic potential for the treatment of alcoholic liver disease. (15th July 2013)

• Record Type: Journal Article
• Authors: Kong, Xiaoni; Feng, Dechun; Mathews, Stephanie; Gao, Bin
• Is Part Of: Journal of gastroenterology and hepatology. Volume 28(2013)Supplement 1
• Page Start: 56
• Page End: 60
• Publication Date: 2013-07-15
• Subjects: hepatic stellate cells -- liver fibrosis -- liver progenitor cells -- senescence; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12032
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Interleukin‐22 (IL‐22) plays a key role in promoting antimicrobial immunity and tissue repair at barrier surfaces by binding to the receptors IL‐22R1, which is generally thought to be expressed exclusively in epithelial cells, and IL‐10R2. Our laboratory previously demonstrated that IL‐22 plays an important role in ameliorating liver injury in many rodent models by targeting hepatocytes that express high levels of IL‐22R1 and IL‐10R2. Recently, we have identified high expression levels of IL‐22R1 and IL‐10R2 in liver progenitor cells and hepatic stellate cells (HSCs). Overexpression of IL‐22 in vivo or treatment with IL‐22 in vitro promotes proliferation of liver progenitor cells via a signal transducer and activator of transcription 3 (STAT3)‐dependent mechanism. IL‐22 treatment also prevents HSC apoptosis in vitro and in vivo . Surprisingly, overexpression of IL‐22, via either gene targeting or exogenous administration of adenovirus expressing IL‐22, reduces liver fibrosis and accelerates the resolution of liver fibrosis during recovery. The anti‐fibrotic effects of IL‐22 are mediated via the activation of STAT3 in HSCs and subsequent induction of suppressor of cytokine signaling 3, which induces HSC senescence. Taken together, the hepatoprotective, mitogenic, and anti‐fibrotic effects of IL‐22 are beneficial in ameliorating alcoholic liver injury. Importantly, due to the restricted expression of IL‐22R1, IL‐22 therapy is expected to have few side effects, thus making IL‐22 a potential candidate for treatment of alcoholic liver disease.